

Regimen Reference Order – CUTA – ipilimumab

ARIA: CUTA - [ipilimumab]

Planned Course: Every 21 days for 4 cycles

Indication for Use: Melanoma, Unresectable or Metastatic

Drug Alert: Immune Checkpoint Inhibitor

CVAD: At Provider’s Discretion

Proceed with treatment if:

- *ANC equal to or greater than 1.5 x 10⁹/L AND Platelets equal to or greater than 50 x 10⁹/L*
- *AST/ALT less than 3 times upper limit of normal*
- *Total bilirubin less than 1.5 times upper limit normal*
- *Creatinine clearance greater than 30 mL/min*
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – CUTA - ipilimumab

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
ipilimumab	3 mg/kg	IV in normal saline 100 mL over 90 minutes <i>Use 0.2 or 0.22 micron filter</i>

All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See CUTA DSG – Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

All Cycles

- CBC, creatinine, electrolytes, liver enzymes, total bilirubin, glucose and TSH as per Physician Orders
- Cortisol level as per Physician Orders
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required
- Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications		
Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
 - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted

ADDITIONAL INFORMATION

- ipilimumab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated
- Administration site restrictions are in place for ipilimumab. ipilimumab should only be administered at a facility where pharmacy compounding occurs on site